NEW YORK, Oct. 12, 2005 (PRIMEZONE) -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(r) (EIO(r)) on London-based Amarin Corporation plc (Nasdaq:AMRN). The full 56-page report can be found at www.crystalra.com, or through a link located in the Investor Relations section of the Amarin Corporation web site at www.amarincorp.com. This report was paid for by Amarin Corporation.
Amarin Corporation is a neuroscience company focused on the research, development, and commercialization of novel drugs to treat central nervous system (CNS) disorders, with a particular emphasis on neurological diseases and disorders. The Company's most advanced product, Miraxion(tm), is in Phase III development for Huntington's disease (HD) and in Phase II for depressive disorders. The Company is using a proprietary technology platform based on an understanding of the chemical nature of the brain. Amarin's lipophilic drugs are predominantly fat-soluble and thus can easily cross the blood-brain barrier into the brain, conferring many advantages over traditional treatments. HD is a lethal, autosomal dominant, genetic disease, characterized by severe movement disorder, dementia, and psychiatric disturbance. There is currently no approved treatment for this disease in the U.S. Miraxion(tm) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for HD and has received Orphan Drug Status in the U.S. and Europe.
Depression is one of the most common mental illnesses, affecting more than 19 million people in the U.S. and representing a $14 billion market dominated by selective serotonin reuptake inhibitors (SSRIs). About one-third of depressed patients fail to respond to standard drugs and another third show only partial response. Miraxion(tm) has been shown in Phase II clinical trials to benefit those individuals who do not respond to current anti-depressants.
Amarin is listed on the NASDAQ small cap market under the symbol AMRN. The Company is headquartered in London, England, with a research and development facility in Stirling, Scotland.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality fee-based research to small and mid-cap companies. The Company's unique and novel product, the Executive Informational Overview(r) (EIO(r)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(r) presents a crystal-clear, detailed report on a company (whether public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(r) details a company's product/technology/service offerings, market size(s), key intellectual property (IP), leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Please see back of report for complete Company disclosures.
Forward-Looking Safe Harbor Statement
To the extent that this release discusses any expectations concerning future plans, financial results or performance, such statements are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and are subject to substantial risks and uncertainties. Actual results could differ materially from those anticipated in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and reflect only management's belief and expectations based upon presently available information. These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates, LLC assumes no obligation to update any of the forward-looking statements in this release.